Drug class
Nitro-dihydro-imidazooxazole antimycobacterial agent; mycolic-acid synthesis inhibitor
Mechanism of action
A prodrug activated by the mycobacterial F420-dependent nitroreductase pathway. Its active metabolites inhibit synthesis of methoxy- and keto-mycolic acids, disrupting the mycobacterial cell wall.
General use cases
- Part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adults, adolescents, children and infants weighing at least 10 kg when an effective regimen cannot otherwise be composed because of resistance or tolerability; follow current national TB guidance
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
